BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33216113)

  • 1. Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo J; Cass L; Murray A; Woodward K; Meals E; Coates M; Daly L; Wheeler V; Mori J; Brindley C; Davis A; McCurdy M; Ito K; Murray B; Strong P; Rapeport G
    J Infect Dis; 2022 Jun; 225(12):2087-2096. PubMed ID: 33216113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
    Brookes DW; Coates M; Allen H; Daly L; Constant S; Huang S; Hows M; Davis A; Cass L; Ayrton J; Knowles I; Strong P; Rapeport G; Ito K
    Br J Pharmacol; 2018 Jun; 175(12):2520-2534. PubMed ID: 29579332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
    Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
    DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
    Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
    N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
    Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
    J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
    DeVincenzo JP; McClure MW; Symons JA; Fathi H; Westland C; Chanda S; Lambkin-Williams R; Smith P; Zhang Q; Beigelman L; Blatt LM; Fry J
    N Engl J Med; 2015 Nov; 373(21):2048-58. PubMed ID: 26580997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
    Schmoele-Thoma B; Zareba AM; Jiang Q; Maddur MS; Danaf R; Mann A; Eze K; Fok-Seang J; Kabir G; Catchpole A; Scott DA; Gurtman AC; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA
    N Engl J Med; 2022 Jun; 386(25):2377-2386. PubMed ID: 35731653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
    Ferrero F; Lin CY; Liese J; Luz K; Stoeva T; Nemeth A; Gijón M; Calvo C; Natalini S; Toh TH; Deleu S; Chen B; Rusch S; Sánchez BL; Leipoldt I; Vijgen L; Huntjens D; Baguet T; Bertzos K; Gamil M; Stevens M;
    Paediatr Drugs; 2024 Jul; 26(4):411-427. PubMed ID: 38649595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral GS-5806 activity in a respiratory syncytial virus challenge study.
    DeVincenzo JP; Whitley RJ; Mackman RL; Scaglioni-Weinlich C; Harrison L; Farrell E; McBride S; Lambkin-Williams R; Jordan R; Xin Y; Ramanathan S; O'Riordan T; Lewis SA; Li X; Toback SL; Lin SL; Chien JW
    N Engl J Med; 2014 Aug; 371(8):711-22. PubMed ID: 25140957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    Sadoff J; De Paepe E; DeVincenzo J; Gymnopoulou E; Menten J; Murray B; Rosemary Bastian A; Vandebosch A; Haazen W; Noulin N; Comeaux C; Heijnen E; Eze K; Gilbert A; Lambkin-Williams R; Schuitemaker H; Callendret B
    J Infect Dis; 2022 Aug; 226(3):396-406. PubMed ID: 33400792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
    Nilsson AC; Pullman J; Napora P; Luz K; Gupta A; Draghi J; Guzman Romero AK; Aggarwal N; Petrova G; Ianus J; Vijgen L; Scott J; Sinha R; Rusch S; Huntjens D; Bertzos K; Stevens M;
    Clin Microbiol Infect; 2023 Oct; 29(10):1320-1327. PubMed ID: 37422079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
    Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
    Martinón-Torres F; Rusch S; Huntjens D; Remmerie B; Vingerhoets J; McFadyen K; Ferrero F; Baraldi E; Rojo P; Epalza C; Stevens M
    Clin Infect Dis; 2020 Dec; 71(10):e594-e603. PubMed ID: 32201897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium.
    Mirabelli C; Jaspers M; Boon M; Jorissen M; Koukni M; Bardiot D; Chaltin P; Marchand A; Neyts J; Jochmans D
    J Antimicrob Chemother; 2018 Jul; 73(7):1823-1829. PubMed ID: 29596680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.
    Marty FM; Chemaly RF; Mullane KM; Lee DG; Hirsch HH; Small CB; Bergeron A; Shoham S; Ljungman P; Waghmare A; Blanchard E; Kim YJ; McKevitt M; Porter DP; Jordan R; Guo Y; German P; Boeckh M; Watkins TR; Chien JW; Dadwal SS
    Clin Infect Dis; 2020 Dec; 71(11):2787-2795. PubMed ID: 31915807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of Respiratory Syncytial Virus (RSV) Memphis Strain 37 (M37) Infection in the Respiratory Tract of Newborn Lambs as an RSV Infection Model for Human Infants.
    Larios Mora A; Detalle L; Van Geelen A; Davis MS; Stohr T; Gallup JM; Ackermann MR
    PLoS One; 2015; 10(12):e0143580. PubMed ID: 26641081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant.
    Gottlieb J; Torres F; Haddad T; Dhillon G; Dilling DF; Knoop C; Rampolla R; Walia R; Ahya V; Kessler R; Budev M; Neurohr C; Glanville AR; Jordan R; Porter D; McKevitt M; German P; Guo Y; Chien JW; Watkins TR; Zamora MR
    J Heart Lung Transplant; 2023 Jul; 42(7):908-916. PubMed ID: 36964084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
    Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.